NEIL3 and cancer: Together, the results demonstrate that the association between NEIL3 expression and neoantigen burden, TMB, and MSI was cancer dependent, implicating that NEIL3 may correlate with some factors that tend to increase responsiveness to checkpoint blockade therapy in a small subset of tumors, which provides a clue for clinical practice.